SEC-sourced researchBeta

HRMY

Harmony Biosciences Holdings, Inc.

US markets

Data passport

CIK: 0001802665
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 18, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

HRMY · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	582,022,000.0000	Feb 24, 2026
December 2024	714,734,000.0000	Feb 24, 2026
December 2025	868,453,000.0000	Feb 24, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	868,453,000.0000	158,687,000.0000	348,199,000.0000	1,271,631,000.0000	401,413,000.0000	Feb 24, 2026
December 2024	714,734,000.0000	145,493,000.0000	219,821,000.0000	999,200,000.0000	340,045,000.0000	Feb 24, 2026
December 2023	582,022,000.0000	128,853,000.0000	219,387,000.0000	—	—	Feb 24, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$868.45M	December 2025	Feb 24, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$714.73M	December 2024	Feb 24, 2026	10-K
Net incomeNetIncomeLoss	$158.69M	December 2025	Feb 24, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$348.2M	December 2025	Feb 24, 2026	10-K
Total assetsAssets	$1.27B	December 2025	Feb 24, 2026	10-K
Total liabilitiesLiabilities	$401.41M	December 2025	Feb 24, 2026	10-K

New filings

Explore methodology ↗